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Stone-forming potential of milk or calcium-fortified orange juice in
idiopathic hypercalciuric adults. Milk and orange juice (OJ) fortified with
calcium-citrate-malate (CCM; calcium-citrate-malate salt is a coined
term to describe a trademarked calcium delivery system found only in
Citrus Hill Plus Calcium) were evaluated for their potential to alter
urine chemistries and crystallization during the course of an eleven
week, crossover study. Six male and six female, non-stone-forming,
idiopathic hypercalciuric adults consumed 600 mg per day as beverage
calcium for four consecutive weeks. The results show that both milk
and CCM-foj-tified OJ (CCM-OJ) were well tolerated by male and
female hypercalciurics since few significant changes occurred in overall
urinary chemistry profiles. CCM-OJ did, however, significantly (P a
0.05) increase urinary pH relative to milk in both sexes and urinary
citrate concentration in women only. Both of these urinary parameters
were significantly increased by CCM-OJ in both sexes relative to the
basal period. The combined pH and citrate effects are recognized to
protect against calcium oxalate stone formation through formation of
the soluble calcium citrate salt. These data indicate that either milk or
CCM-fortified orange juice can be consumed, at least within the limits
tested, as a dietary source of calcium without increasing the risk of
stone formation in a calcium-sensitive subpopulation. That the urine
chemistries and crystallization of such calcium-sensitive individuals
does not significantly change with the consumption of either beverage
implies that the urine of normal individuals would be exceedingly
unlikely to change as well.
Calcium oxalate is the most common crystal in kidney stones
in the United States, accounting for about 80% of all stones
analyzed [lj. Idiopathic or hereditary [2] hypercalciuria raises
the supersaturation of the urine with respect to calcium oxalate
[31 and is the most frequent metabolic abnormality responsible
for calcium stones. Approximately 50% of men and 75% of
women with stones are hypercalciuric [4]. The genetic trait is
present in about 5 to 10% of the population, regardless of age.
People with hypercalciuria hyperabsorb calcium from their
diets and partially excrete the calcium in their urine [5]. It is
generally recognized that calcium loads from diet or medica-
tions are associated with an increased risk for kidney stone
formation in susceptible individuals.
Urinary citrate is a physiologic defense mechanism against
calcium stones. The anion is recognized to bind calcium in the
soluble calcium citrate salt, thus depriving urinary oxalate of
calcium and preventing the formation or continued growth of an
insoluble calcium oxalate crystal. Urinary citrate excretion
rates of stone-forming men and women are known to be lower
than those observed in adults without stones [61. Urinary
oxalate excretion, however, tends to be similar in stone formers
and normals when compared to the same gender. Malate,
another small-molecular-weight, multicarboxylic acid, also
forms soluble calcium salts and oral doses have been shown to
protect against experimental urolithiasis in the rat [7, 8].
The physiochemical properties of citrate have resulted in the
therapeutic use of potassium citrate as an effective oral treat-
ment for stone disease 19—111. This anion has lead also to the
development of calcium citrate which has been reported to be a
bioavailable source of calcium [121 that, due to the attendant
rise in urinary citrate excretion, does not increase the risk of
calcium stone formation in healthy adults [13]. Soluble malate
salts may also provide some protection against calcium oxalate
stone formation, although this concept has not been clinically
tested.
In total, these data suggest that orange juice fortified with a
mixed calcium-citrate-malate salt (CCM), a coined term to
describe the trademarked calcium delivery system resulting
from the combination of calcium and organic acids found only
in Citrus Hill Plus Calcium, may attenuate the risk associated
with its likely calciuric effects. Bioavailability tests in both rats
and humans have shown that this calcium source is absorbed at
least as well as, if not better than, calcium carbonate or milk
[14]. CCM, and the orange juice itself [15], also would provide
both citrate and malate which has the potential to enhance
urinary excretion of both carboxylic acids. Thus, we report
here on the changes in urinary supersaturations in healthy,
non-stone-forming male and female hypercalciurics who con-
sumed CCM-fortified orange juice (CCM-OJ) or milk in a
nonresident crossover design study. Hypercalciurics were cho-
sen in preference to otherwise normal adults since this sub-
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Six men and six women, ages 18 to 30, were recruited from
our pool of previously studied normal adults and from non-
stone-forming relatives of hypercalciuric nephrolithiasis pa-
tients. All subjects were hypercalciuric, based upon the mean of
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Males Females
Number of subjects 6 6
Total number of observations 21 19
Urine volume liters 1.35 0,14 1,58 0.17
Body weight kg 64.7 1.4 53.9 1.0
Urinary calcium mg/24 hr 316 33 235 19
Urinary creatinine mg/24 hr 2.00 0.10 1.23 0.06
Ca:Cr ratio mg/24 hr 155 10 195 16
at least three 24-hour urine collections, by one or more of the
following criteria: >250 mg calcium/24 hr (women), >300 mg
calciuml24 hr (men) or >140 mg calcium/g creatinine for either
gender (P C 0.05 vs. normals). Results of these and other
screening measurements are provided in Table 1. All were
judged to be otherwise healthy based upon medical history and
a pretreatment medical examination. The subjects submitted a
seven-day diet diary which verified that they consumed less
than 800 mg calcium/day and did not practice a fadist diet. Any
subjects were excluded if they used medications, mineral or
vitamin supplements, had citrus allergies or lactose intolerance,
or were pregnant or nursing females. All subjects signed an
approved consent form. The study was reviewed and approved
by the Institutional Review Board of the University of Chicago.
The design was an open, crossover, nonresident study con-
sisting of two treatment phases 28 days in length (Periods I and
2), two seven-day baseline periods and a seven-day washout
period at the start of the study and again between treatments. A
chronology of the experimental periods is provided in Table 2.
Subjects were instructed to maintain their usual dietary habits,
with the exception that they must avoid voluntary milk con-
sumption during all phases of the study. This restriction was
imposed because it seemed unlikely that subjects would be able
to maintain a representative pattern of typical fluid milk intake
during the milk treatment phase. All subjects were advised also
to avoid excessive consumption of all dairy products through-
out the study, although total dietary calcium intake was not
controlled in either the basal, treatment or washout phases.
This design thus evaluated the effect of dietary supplements of
calcium on urinary supersaturation among a group of hypercal-
ciuric adults who chose their own diets. Such a design was
considered more realistic and sophisticated than one where
diets would be rigidly malntained in a metabolic ward setting.
Treatment phases consisted of each subject consuming two
six-ounce glasses of CCM-OJ or two eight-ounce glasses of 2%
milk, once in the morning and once in the afternoon, with or
without food. Both calcium-containing beverages differed by
calcium content but each added about 600 mg calcium/day to
their daily dietary intake• of calcium. All subjects were ran-
domly allocated to either CCM-OJ or milk treatment and
crossed over to the alternative beverage on day 49.
Urinary measurements
Twenty-four hour urines were collected for each subject
during screening, at baseline (days 7 or 49), on days 14, 21, 28,
and 35 in the first treatment phase, and days 56, 63, 70 and 76 in
the last treatment phase. Urinary volume, calcium, citrate,




malate, pH and creatinine were measured during screening and
on the first three collections of each treatment phase. These
measurements, especially the calcium-citrate index [61 provided
a preliminary assessment of any increasing risk for stone
formation. Urinary oxalate, uric acid, sodium, potassium, sul-
fate, phosphate, chloride and magnesium were measured also
on the last collection day of each treatment phase. The com-
plete set of data on the last day of treatment was then analyzed
to provide a more definitive estimate of stone formation risk
based upon a computer-derived calculation of supersaturations.
Analytical methods
Calcium and magnesium were measured by atomic absorp-
tion spectrometry, oxalate by the zinc reduction method, citrate
by the citrate lyase method, uric acid by the uricase method,
sodium and potassium by flame photometry, phosphate and
creatinine by autoanalyzer, sulfate by turbidometry, chloride
by electrometric titration and malate by a coupled enzyme
system. Supersaturations were calculated by Equil [16], a
computer program that calculates relative supersaturations with
stone-forming salts from the calculated ions and interactions of
complexes in the urine at a known pH. Calcium:citrate scores
for estimating risk of stone formation were calculated from
previously published equations [61.
Statistics
All results were statistically analyzed by unpaired t-tests
without assumption of equal variance. Results were considered
statistically significant if P  0.05.
Results
Daily urine creatinines (Tables 3 and 4) were the same for all
subjects of each gender during the basal, CCM-OJ and milk
treatment periods. Urine creatinine is the standard, accepted
marker for completeness of urine collection. That these values
Table 1. Summary of screening results for subjects selected to
participate in the study
Clinical measurements are expressed as the mean 5EM.
Baseline 1 1—7
(Discontinue fluid milk consumption for the remainder of the study.)
Collect basal 24 hr urine 6—7 X
Begin beverage one 7 —
Collect24 hr urine 13—14 X
Collect 24 hr urine 20—21 X
Collect 24 hr urine 27—28 X
Collect 24 hr urine 34—35 X*
Washout 35—42
Baseline 2 43—49
Collect base 24-hr urine 48—49 X"
Begin beverage two 49 —
Collect 24 hr urine 55—56 X
Collect 24 hr urine 62—63 X
Collect 24 hr urine 69—70 X
Collect 24 hr urine 75—76 X'K
Abbreviations are: XK, calcium, volume, pH, citrate, malate and
creatinine only; X, the full complement of tests to determine urinary
supersaturation.
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Table 3. Chemistries and relative supersaturations of urines obtained
on basal, CCM-OJ and milk treatment in 6 hypercalciuric men
Measurement CCM-OJ Milk Basal
Creatinine g/24 hr 1.94 0.08 1.91 0.09 1.97 0.13
Volume liter/24 hr 1.22 0.08 1.03 0.07 1.24 0.13
pH 6.22 0.09" 5.96 0.08" 5.89 0.08
Calcium mg/24 hr 242 16 234 16 241 30
Calcium:creatinine mg/g 126 7 124 5 122 14
Calcium mg/liter 215 16 243 17 210 25
Oxalatemg/24hr 36±5 39±4 38±6
Citrate mg/24 hr 544 46C 523 38 517 49
Citrate mg/liter 527 70 556 53 484 81
Score —0.25 0.28 —0.37 0.19 —0.15 0.38
Uric acid mg/24 hr 702 131 752 100 760 89
Undissociated uric acid 152 66 116 48 151 22
Sodium mEq/24 hr 124 27 124 15 160 21
Potassium mEq/24 hr 63 11 59 13 61 4
Phosphorus mg/24 hr 876 102 906 62 1063 76
Magnesium mg/24 hr 115 10 117 11 124 12
Chloride mEq/liter 116 19 100 20 136 17
Sulfate mmol/liter 40 5 42 8 40 4
Malic acid mg/dl 27 3 36 4 29 5
Relative supersaturations
Calcium oxalate 8.54 1.30 7.64 0.91 7.22 0.84
Brushite 3.27 0.81 3.55 0.66c 2.59 0.27
Hydroxyapatite 0.31 0.31 0.68 0.55 0.01 0.01
Undissociated uric acid 3.28 1.44 2.49 1.03 3.26 0.48
Sodium monohydrogen 6.79 1.48 7.98 1.54 7.92 1.31
urate
Potassium 1.15 0.40 1.09 0.22 0.86 0.15
monohydrogen urate
Calcium carbonate 7.45 1.71k 5.06 0.77a 1.04 0.14
Values are expressed as the mean SEM. Numbers of measurements
are: basal (12), CCM-OJ and milk (24 each) for creatinine, pH, calcium,
citrate, and malate; basal (12), CCM-OJ and milk (6 each) for oxalate,
uric acid, sodium, potassium, phosphorus, magnesium, chloride, sul-
fate and all relative supersaturations.
ap<0001;bp<000landcp<OOsdiffersfrombasalap<005
differs from CCM-OJ.
were consistent throughout the study demonstrates that collec-
tions were complete and that other urine parameters reflect true
24-hour excretions. Moreover, urine volume, oxalate, sodium,
potassium, magnesium, phosphorus, chloride and sulfate were
not significantly different from each other in the basal periods.
These data show that eating patterns and fluid habits, as judged
by excretion rates, were consistent and stable during the eleven
weeks. However, milk consumption significantly increased (P
<0.05) sodium excretion in women relative to the basal period,
but did not differ in comparison to CCM-OJ. Women also
excreted significantly less undissociated uric acid during
CCM-OJ consumption than during the basal period, although
this parameter did not differ from milk.
Daily urinary calcium excretion among male and female
hypercalciurics was not significantly affected by treatment
(Tables 3 and 4). Thus, despite the addition of 600 mg calcium
to their diet, no more calcium appeared in the urine of subjects
consuming CCM-OJ or commercially available lowfat milk than
during their basal period. The mean 24-hour excretion of citrate
was higher in subjects who consumed CCM-OJ than in any
other treatment regimen. These differences were significant in
comparison to the basal period (P < 0.05 for males, P < 0.01 for
females) but not when compared to milk (P> 0.05). Consump-
tion of CCM-OJ also significantly elevated urinary pH for both
Table 4. Chemistries and relative supersaturations of urines obtained
on basal, CCM-OJ and milk treatment in 6 hypercalciuric women
Measurement CCM-OJ Milk Basal
Creatinine g/24 hr 1.27 0.03 1.31 0.04 1.26 0.03
Volume liter/24 hr 1.66 0.18 1.88 0.16 1.49 0.24
pH 6.54 008b 6.24 o.loe 6.03 0.14
Calcium mg/24 hr 214 15 216 11 180 20
Calcium:creatinine mg/g 171 13 167 9 145 17
Calcium mg/liter 156 15 130 11 166 38
Oxalatemg/24hr 35 7 31 2 34 4
Citrate mg/24 hr 689 30b 586 37 515 47
Citrate mg/liter 540 57 358 31" 428 63
Score 0.46 0.25 0.92 0.17 1.29 0.79
Uric acid mg/24 hr 468 25 542 43 500 28
Undissociated uric acid 21 5C 37 llC 121 44
Sodium mEq/24 hr 130 9 161 12C 121 9
Potassium mEq/24 hr 70 6 71 7 57 5
Posphorus mg/24 hr 747 55 899 63 822 43
Magnesium mg/24 hr 105 9 116 9 102 5
Chloride mEq/liter 100 19 83 11 99 14
Sulfate mmol/liter 21 4 24 5 31 5
Malic acid mg/dl 16 2 12 2 21 5
Relative supersaturations
Calcium oxalate 5.60 0.83 4.07 0.48 5.89 1.01
Brushite 4.13 0.72c 3.20 0.56 2.12 0.42
Hydroxyapatite 3.23 2.67 2.39 1.88 0.05 0.02
Undissociated uric acid 0.46 0.l1' 0.79 0.23 2.64 0.97
Sodium monohydrogen 5.01 1.62 4.59 1.94 4.79 1.25
urate
Potassium 0.77 0.25 0.53 0.18 0.62 0.16
monohydrogen urate
Calcium carbonate 8.92 2.26" 5.70 l.00 1.49 0.34
Values are expressed as the mean SEM. Numbers of measurements
are: basal (12), CCM-OJ and milk (24 each) for creatinine, pH, calcium,
citrate, and malate; basal (12), CCM-OJ and milk (6 each) for oxalate,
uric acid, sodium, potassium, phosphorus, magnesium, chloride, sul-
fate and all relative supersaturations.
P <0.001; b P <0.01 and c P <0.05, differs from basal"P <0.05,
and e P <0.01, differs from CCM-OJ.
men and women in comparison to the basal and milk periods
with P < 0.01 and P < 0.05, respectively. Not surprisingly,
females had higher pH values than men at all phases of the
study.
Relative supersaturations for calcium oxalate and various
salts of uric acid were not different across the three groups
(Tables 3 and 4). Supersaturations for brushite in male subjects
receiving milk, and females consuming CCM-OJ, were greater
than basal with P <0.05. In a similar manner, supersaturation
of calcium carbonate was also significantly elevated in all
treated subjects with P ranging from <0.01 to <0.001 for both
CCM-OJ and milk relative to the basal period. These later
effects are due to the treatment-related rise in urinary pH which
is recognized to promote formation of both brushite and cal-
cium carbonate crystals.
Discussion
Compared to milk, CCM-OJ had no effects upon urine
chemistries in hypercalciuric adults except to increase urine pH
and citrate excretion. A rise in pH tends to enhance formation
of insoluble calcium phosphate salts as indicated by the slightly
elevated supersaturations of brushite and apatite for women
consuming CCM-OJ versus milk. These latter effects would
have little clinical relevance since calcium phosphate stones are
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exceedingly rare and the increase in supersaturations insignifi-
cant. These increases could promote stones through formation
of nucleating centers for calcium oxalate, but the CCM-OJ and
milk seem equal in this regard. The pH and citrate changes
prevent increased calcium oxalate supersaturation which is the
most clinically relevant stone to adult Americans [17]. This
protection is provided by citrate's reduction of the calcium free
ion level through formation of the soluble calcium citrate salt.
It is of particular interest to note that these results were
obtained in adults with familial hypercalciuria, who absorb
dietary calcium at higher rates than normals and who excrete a
portion of the absorbed calcium in their urine at an abnormally
high rate [18]. They are known to respond to calcium loading
with a much higher increase of urine calcium than normal
people and their hypercalciuria is the most common established
risk factor for calcium nephrolithiasis [19]. The results of the
present study show that hypercalciuric people who consume
CCM-OJ do not appear to be at additional risk of stone
formation within the levels of consumption tested. That these
people did not increase their risk to form calcium-containing
kidney stones when consuming CCM-fortified orange juice
strongly implies that normal people are most exceedingly un-
likely to do so.
Despite the fact that animal and human studies have shown
that milk and CCM are well absorbed sources of dietary calcium
with fractional absorption in the 25 to 35% range [14], results of
the present study failed to show a calciuric response in hyper-
calciuric adults who consumed about 600 mg of calcium as
either CCM-OJ or milk. Urine calcium output in both normals
and hypercalciurics is positively correlated with dietary calcium
across a wide range of calcium intake [20, 21]. The lack of
increase in urinary calcium excretion during treatment in the
present study most likely indicates that subjects self-selected
relatively equal levels of total dietary calcium intake across all
phases of the study. This response is viewed as a strength of
this study since it reflects the clinical consequences of eating a
complex diet providing varying amounts of total calcium.
This study also documents for the first time the clinical
acceptability of milk as a dietary calcium source for hypercal-
ciurics. Low calcium diets are not appropriate for stone patients
because urinary excretion of calcium remains elevated which
results in negative calcium balance [22]. Thus, patients are
advised to manage stone risk by restricting their calcium intake
to 400 to 1000 mg/day [23]. Clinicians have recognized that daily
calcium needs are best met with dairy products while such
supplemental calcium sources as calcium carbonate can exac-
erbate the disease by raising urinary supersaturations of various
insoluble calcium salts. Results of the present study now show
that as much as 600 mg calcium from milk can be added to other
dietary sources and not result in any appreciable change in
calcium oxalate supersaturation. Likewise, the results also
clearly demonstrate that CCM-OJ is a safe and acceptable
alternative to milk for those stone patients who are intolerant to
this latter beverage or simply chose to avoid milk in their diet.
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